{
    "@graph": [
        {
            "@id": "gnd:4059798-2",
            "sameAs": "Therapie"
        },
        {
            "@id": "gnd:4073781-0",
            "sameAs": "Krebs (Medizin)"
        },
        {
            "@id": "gnd:4144501-6",
            "sameAs": "Benzimidazol"
        },
        {
            "@id": "gnd:4144502-8",
            "sameAs": "Benzimidazolderivate"
        },
        {
            "@id": "gnd:7566079-9",
            "sameAs": "Epigenetik"
        },
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A748773584",
            "@type": "bibo:Thesis",
            "P1053": "Online-Ressource (PDF-Datei: 208 S., 7338 KB)",
            "creator": "El Gaghlab, Khattab",
            "description": "Ill., graph. Darst.",
            "identifier": [
                "(firstid)GBV:748773584",
                "(ppn)748773584"
            ],
            "publisher": "Universit√§tsbibliothek",
            "subject": [
                "(classificationName=ddc-dbn)540",
                "(classificationName=linseach:mapping)che",
                "(classificationName=bk, id=106409026)44.48 - Medizinische Genetik",
                "(classificationName=bk, id=18157179X)44.42 - Pharmazeutische Chemie",
                "(classificationName=linseach:mapping)meda",
                "(classificationName=ddc-dbn)610"
            ],
            "title": "Benzimidazolone und Benzimidazolthione als neue Modulatoren epigenetischer Prozesse",
            "abstract": [
                "Epigenetik, Krebstherapie, epigenetic",
                "The natural product splitomicin is known as selective inhibitor of NAD+-dependant histon deacetylases (produced by the Sir2-protein) and was starting point of the investigations described. However, splitomycin is not active with respect to human enzymes and prone to rapid hydrolysis in the human body and thus neither suited as drug candidate nor as a scaffold for the construction of diversity. Because the stability of compounds intended to effect biological systems is a prerequisite for activity and a shift of selectivity from yeast to human enzymes was envisioned, splitomicin was used as a lead structure in the broader sense. Thus, the heterocyclic ring system was modified on the basis of structure-activity-relationships. The six-membered ring of the pyranone moiety of splitomicin was replaced by a five-membered ring. Annelated imidazolones, imidazolthiones, and quinolino-imidazolthiones were synthesized to adress stability issues and to obtain the desired activity."
            ],
            "contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": "(collectioncode)GBV-ODiss",
            "issued": "2013",
            "language": "http://id.loc.gov/vocabulary/iso639-1/de",
            "license": "open access",
            "medium": "rda:termList/RDACarrierType/1018",
            "dcterms:subject": [
                {
                    "@id": "gnd:4059798-2"
                },
                {
                    "@id": "gnd:4144502-8"
                },
                {
                    "@id": "gnd:4073781-0"
                },
                {
                    "@id": "gnd:4144501-6"
                },
                {
                    "@id": "gnd:7566079-9"
                }
            ]
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "sameAs": "http://www.w3.org/2002/07/owl#sameAs",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "title": "http://purl.org/dc/elements/1.1/title",
        "abstract": "http://purl.org/dc/terms/abstract",
        "description": "http://purl.org/dc/elements/1.1/description",
        "license": "http://purl.org/dc/terms/license",
        "contributor": "http://purl.org/dc/terms/contributor",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "creator": "http://purl.org/dc/elements/1.1/creator",
        "issued": "http://purl.org/dc/terms/issued",
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}